Obesity
← Earnings Calls
01
02
03
04 05 06
Tone
AI
Capex
A1 A2 A3
PFE
FY2025 Q4
Improving
Pfizer, Inc. earnings call
Buzzberg read
Monthly GLP-1 3944 could be competitive and best-in-class among mono agonists
Pfizer reported a strong 2025 with solid operational growth excluding COVID, driven by new product launches and cost discipline. The key focus on the call was the positive preliminary data for its monthly-dosed obesity drug candidate (danuglipron/3944), which validates its differentiation strategy. Management reaffirmed 2026 guidance reflecting LOE headwinds and continued investment. 2025 full-year revenue was $62.6B (down 2% operational), with 6% operational growth excluding COVID products.
Buzzberg read Monthly GLP-1 3944 could be competitive and best-in-class among mono agonists Pfizer reported a strong 2025 with solid operational growth excluding COVID, driven by new product launches and cost discipline. The key focus on the call was the positive preliminary data for its monthly-dosed obesity drug candidate (danuglipron/3944), which validates its differentiation strategy. Management reaffirmed 2026 guidance reflecting LOE headwinds and continued investment. 2025 full-year revenue was $62.6B (down 2% operational), with 6% operational growth excluding COVID products. Read full analysisCollapse analysis
Pfizer reported a strong 2025 with solid operational growth excluding COVID, driven by new product launches and cost discipline. The key focus on the call was the positive preliminary data for its monthly-dosed obesity drug candidate (danuglipron/3944), which validates its differentiation strategy. Management reaffirmed 2026 guidance reflecting LOE headwinds and continued investment. 2025 full-year revenue was $62.6B (down 2% operational), with 6% operational growth excluding COVID products.
- Pipeline prioritization led to a $4.4B non-cash impairment, including deprioritizing disitamab vedotin in bladder cancer.
- Positive Phase 2b VESPR-3 data for obesity drug 3944 showed ~10-12.3% placebo-adjusted weight loss with monthly dosing, supporting plans for Phase 3.
- Management reaffirmed FY2026 revenue guidance of $59.5-62.5B and EPS of $2.80-3.00.
Revenue$17.557BReported
EPS$0.66Reported
Gross margin69.97%Reported
Operating margin21.01%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Obesity/Pipeline
Pfizer targets first obesity portfolio approvals in 2028
AI
Pfizer expanding AI compute capacity to over 1,200 GPUs
Show 3 more callouts
Guidance
Management reaffirms FY2026 guidance
Capital allocation
Pfizer prioritizes maintaining and growing dividend
Growth strategy
Company expects end-of-decade growth from pipeline, BD, and launches
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $17.557B | Reported |
| EPS | $0.66 | Reported |
| Gross margin | 69.97% | Reported |
| Operating margin | 21.01% | Reported |
| Free cash flow | $4.504B | Reported |
| Capex | $0.845B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $2.80–$3.00 | $2.90 | Maintained |
| Revenue | FY2026 | $59.5B–$62.5B | $61B | Maintained |
AI, capex & demand read
Management read
Upbeat
Management repeatedly characterized 2025 as a very good year, emphasized over-delivery on commitments, and expressed confidence in the pipeline and 2026 catalysts.
Management AI read
Management is aggressively scaling AI across R&D, manufacturing, and commercial, framing it as a key productivity lever. It plans to expand to more than 1,200 GPUs over the next two years and says AI is already improving launch execution, marketing ROI, and cost savings.
Investment and capacity
AI-related infrastructure investment is directionally increasing — management plans to expand to more than 1,200 GPUs, largely for R&D. Manufacturing optimization is also ongoing, with additional savings targeted in 2026 and 2027, though no total capex figure was provided.
all 6 named companies below
Companiesreturns since call
Partners
Partners
Dave Denton
Pfizer's COVID product partnership with BioNTech continues to be a significant driver of reported financials, with a 50-50 profit split on Comirnaty, though the revenue decline for COVID products is factored into guidance.
Evidence
“as well as continued strong cost management. Future improvements in our manufacturing footprint remain a top priority going forward. As a reminder, over the past two years, our adjusted gross margins have generally remained in the mid to”
Partners
Dave Denton
The planned divestment of Pfizer's stake in ViiV Healthcare (a GSK-partnered HIV JV) provides significant capital for business development.
Evidence
“Additionally, the planned sale of our stake in VEV will further improve our balance sheet. When including the VEV proceeds, we have approximately $7 billion in BD capacity.”
Investees
Investees
Dr. Chris Boshoff
Seagen integration is successful, providing a robust pipeline (ADCs like PADSEV) and maintaining talent, positioning Pfizer for oncology growth.
Evidence
“We have a vibrant community of scientists and clinicians in Seattle. I believe we're one of the biggest employers in the biotech or biopharma industry in that region. Most of the colleagues actually remained at Pfizer, which is a testament”
Supply chain
Supply chain
Dave Denton
Pfizer's pipeline prioritization has led to a ~$4.4B non-cash impairment, including deprioritizing disitamab vedotin in bladder cancer due to competition from its own PADSEV, indicating a strategic resource shift within oncology. — Shows a direct market access trade-off between Roche's Padcev and its own pipeline, potentially reducing future competitive pressure from a different mechanism of action.
Evidence
“It is important to note that one of the asset indications we deprioritized was disidimab vedotin in bladder cancer is largely the result of the recently strong study readouts expanded indications, and related higher long-term revenue”
Supply chain
Dr. Chris Boshoff
Acknowledges that the VESPR-3 trial design had no down-titration allowed, an unusual feature for obesity trials, suggesting the trial may have understated the drug's true tolerability/effectiveness profile. — Indicates the trial results may be conservative; allowing down-titration in Phase III could improve tolerability and thereby commercial success, competing directly with Lilly and Novo's products.
Evidence
“Just to remember for this study, there was no step-down titration was allowed, which is unusual for obesity trials. But that will obviously not happen in the phase three study. We will allow down titration.”
External signals
Supply-chain alpha · 3returns since call
Pfizer's pipeline prioritization has led to a ~$4.4B non-cash impairment, including deprioritizing disitamab vedotin in bladder cancer due to competition from its own PADSEV, indicating a strategic resource shift within oncology.
Evidence
“It is important to note that one of the asset indications we deprioritized was disidimab vedotin in bladder cancer is largely the result of the recently strong study readouts expanded indications, and related higher long-term revenue proje…”
The obesity market is cited as being largely out-of-pocket (OOP) with high willingness to pay (~$250-350/month), which may alter standard reimbursement expectations and speed market access.
Evidence
“First is the out-of-pocket category... we see that there are high willingness to pay out-of-pocket across all mature markets... and we see the price point being across 250 to 350.”
Acknowledges that the VESPR-3 trial design had no down-titration allowed, an unusual feature for obesity trials, suggesting the trial may have understated the drug's true tolerability/effectiveness profile.
Methodology & coverage
Management-only analysis. All 6 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.